Citadel Advisors’s Mineralys Therapeutics MLYS Stock Holding History

Citadel Advisors’s Portfolio MLYS Stock Details MLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.42M	Buy	89,500 +29,900	+50%	+$877K	﹤0.01%	5687
2025 Q4	$2.16M	Buy	59,600 +27,800	+87%	+$1.11M	﹤0.01%	5752
2025 Q3	$1.21M	Buy	+31,800	New	+$688K	﹤0.01%	7133
2025 Q2	–	Sell	-9,100	Closed	-$145K	–	14090
2025 Q1	$145K	Buy	+9,100	New	+$105K	﹤0.01%	10934
2024 Q4	–	Sell	-8,300	Closed	-$101K	–	15052
2024 Q3	$101K	Sell	8,300 -8,700	-51%	-$105K	﹤0.01%	11107
2024 Q2	$199K	Buy	17,000 +7,000	+70%	+$88.2K	﹤0.01%	9954
2024 Q1	$129K	Buy	10,000 +9,500	+1,900%	+$117K	﹤0.01%	10990
2023 Q4	$4.3K	Buy	+500	New	+$3.93K	﹤0.01%	13520

Other funds holding MLYS

Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Citadel Advisors's MLYS Position: Q1 2026 in Review

Citadel Advisors increased its Mineralys Therapeutics (MLYS) stake by 50% in Q1 2026, buying an estimated $5.87M and bringing the position to 600,041 shares worth $16.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2593.

Citadel Advisors first reported a position in MLYS in Q1 2023 and has held it in 11 quarters since. The position peaked at $78.4M in Q3 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

Citadel Advisors held 600,041 shares of Mineralys Therapeutics worth $16.3M as of Q1 2026.
Citadel Advisors bought 200,122 Mineralys Therapeutics shares in Q1 2026, an estimated $5.87M.
Mineralys Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2593 holding.
Citadel Advisors first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 11 quarters since.
Citadel Advisors's Mineralys Therapeutics position peaked at $78.4M in Q3 2025.
214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.